Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego · 2025
Aberrant expression of CD markers in patients with acute leukemia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Habeeb Aymen Radhi, Al-Tameemi Hamid, Abdullah Dina A A, Al-Hussein Rand Muhammed Abdul-Hussein, Ahmed Ali Khudhair
Аннотация
OBJECTIVE: Aim: The current study designed to evaluate the abnormal expression prevalence of Cluster of Differentiation (CD) markers in Iraqi patients diagnosed with AL at the Medical City Hospitals.
PATIENTS AND METHODS: Materials and Methods: A total of 175 newly diagnosed leukemia patients (110 males and 65 females) aged between 1 and 85 years were included. Bone marrow aspiration and flow cytometry were used to analyze CD marker expression. Data on hematological parameters, immunophenotypic profiles, and demographic characteristics were recorded and statistically analyzed.
RESULTS: Results: The present study identified aberrant expression of CD markers, including CD13, CD19, CD33, CD34, CD117, CD56, CD5, TdT, HLA-DR, and CD79a, across different leukemia subtypes. Acute myeloid leukemia (AML) was the most prevalent subtype (46.2%), followed by B-acute lymphoblastic leukemia (B-ALL) (26.2%) and T-acute lymphoblastic leukemia (T-ALL) (8.5%). CD34 was highly expressed in AML, B-ALL, and T-ALL cases, while CD13 and CD33 were predominantly expressed in AML. CD56 and CD117 were associated with multiple myeloma (MM).
CONCLUSION: Conclusions: The study demonstrated a high ratio of abnormal CD marker expression in AL cases, aligning previous data from various area around the world. Identifying aberrant antigen expression patterns through immunophenotyping aids in diagnosing leukemia and distinguishing neoplastic cells from normal hematopoietic precursors.
PATIENTS AND METHODS: Materials and Methods: A total of 175 newly diagnosed leukemia patients (110 males and 65 females) aged between 1 and 85 years were included. Bone marrow aspiration and flow cytometry were used to analyze CD marker expression. Data on hematological parameters, immunophenotypic profiles, and demographic characteristics were recorded and statistically analyzed.
RESULTS: Results: The present study identified aberrant expression of CD markers, including CD13, CD19, CD33, CD34, CD117, CD56, CD5, TdT, HLA-DR, and CD79a, across different leukemia subtypes. Acute myeloid leukemia (AML) was the most prevalent subtype (46.2%), followed by B-acute lymphoblastic leukemia (B-ALL) (26.2%) and T-acute lymphoblastic leukemia (T-ALL) (8.5%). CD34 was highly expressed in AML, B-ALL, and T-ALL cases, while CD13 and CD33 were predominantly expressed in AML. CD56 and CD117 were associated with multiple myeloma (MM).
CONCLUSION: Conclusions: The study demonstrated a high ratio of abnormal CD marker expression in AL cases, aligning previous data from various area around the world. Identifying aberrant antigen expression patterns through immunophenotyping aids in diagnosing leukemia and distinguishing neoplastic cells from normal hematopoietic precursors.
Предметные рубрики MeSH
Antigens, CDHumansMaleFemaleInfantChild, PreschoolChildAdolescentYoung AdultAdultMiddle AgedAgedAged, 80 and overLeukemia, Myeloid, AcutePrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaGene Expression Regulation, LeukemicBiomarkers, TumorMultiple MyelomaBone MarrowBiopsy, NeedleImmunophenotypingIraqFlow CytometryRetrospective Studies